Adult‐onset linear IgA bullous dermatosis: a retrospective single‐center cohort study of 81 patients and literature review

• Published in: International journal of dermatology 2024-07, Vol.63 (7), p.936-941
• Main Authors: Wang, Katherine L., Lehman, Julia S., Todd, Austin, Davis, Dawn M. R.
• Format: Article
• Language: English
• Subjects: Adult; Age of Onset; Aged; Aged, 80 and over; Blistering; Data collection; Drug Eruptions - diagnosis; Drug Eruptions - epidemiology; Drug Eruptions - etiology; Female; Humans; Immunoglobulin A; Inflammatory bowel disease; Inflammatory bowel diseases; Inflammatory Bowel Diseases - complications; Inflammatory Bowel Diseases - drug therapy; Intestine; Linear IgA Bullous Dermatosis - diagnosis; Linear IgA Bullous Dermatosis - drug therapy; Linear IgA Bullous Dermatosis - epidemiology; Literature reviews; Male; Malignancy; Middle Aged; Neoplasms - complications; Paraneoplastic Syndromes - diagnosis; Paraneoplastic Syndromes - etiology; Paraneoplastic Syndromes - immunology; Recurrence; Retrospective Studies; Skin diseases; Young Adult
• ISSN: 0011-9059; 1365-4632; 1365-4632
• DOI: 10.1111/ijd.17041

Background Linear IgA bullous dermatosis (LABD) is a rare autoimmune blistering disorder that may be drug‐induced or paraneoplastic. We aim to characterize features of LABD and determine differentiating factors among idiopathic, drug‐induced, or malignancy‐associated diseases. Methods We conducted a single‐center retrospective chart review of adult patients with linear IgA bullous dermatosis at a large tertiary referral center and a literature review of adult linear IgA bullous dermatosis. Results Eighty‐one patients were included in the study. Ten patients (12.3%) had comorbid malignancy and nine (11.1%) had inflammatory bowel disease. Median disease duration was significantly shorter in both drug‐induced (1.2 vs. 48.8 months; P